Archives of Pharmacal Research

The Pharmaceutical Society of Korea (대한약학회)
권호 표지

Immunological Properties of Recombinant Hepatitis B Surface Antigen Expressed in Mammalian Cell(C127)

  • Published : 1998.10.01
Download PDF
⟨ Previous Next ⟩

Abstract

We examined the immunological properties of the recombinant hepatitis B surface antigen (r-HBsAg) which was expressed in mammalian cell (C127). The cross-immunity of r-HBsAg and plasma-derived hepatitis B surface antigen (p-HBsAg) were tested using Western blotting and ELISA with guinea pig polyclonal antibody and naturally infected human-derived antibody and the both antigens show the same results in their response pattern and intensity, which indicate they have a good cross-immunity. from the measurement of $ED_{50}$ after formalin- or heat-inactivation, both r-HBsAg and p-HBsAg and p-HBsAg showed $ED_{50}$ of 0.2-0.3 in formalin-inactivaton, while r-HBsAg was 0.05-0.09 and p-HBsAg was 0.03-0.07 in heat-inactivation, which means heat-inactivation method is 3-4 times superior in immunogenicity. In the immunopersistency test performed in guinea pig for the period of 3 months with two different adjuvants, antibody titer was 34.2 with muramyl dipeptide adjuvant, which was 1.8 times greater than the antibody titer of 18.9 with $AIPO_{4}$ adjuvant. the mutagenicity of r-HBsAg has the same cross-immunity with p-HBsAg, and heat-inactivation method and muramyl dipeptide adjuvant allow development of r-HBsAg vaccine with excellent immunogenicity.

Keywords

References

  1. Semin.Immunology v.2 Adjuvant formulations and their mode of action Alison;A.C.;Byars.N.E.
  2. JAMA v.191 A New antigen in leukemia sera Blumberg;B.S.;Alter;H.J.;Visnich;S.
  3. Bull. N.Y.Acad. Med. v.44 Hepatitis and leukemia:their relation to Australia antigen Blumberg;B.S.;Suntnick;A.L.;London;W.T.
  4. 9th Biennial Scientific Meeting of Asian Pacific Association for the Study of Liver Prevention strategery for heptatitis B virus infection with HBsAg immunization in Korea Chung;T.H.
  5. Lancet v.1 Dane;D.S.;Cameron;C.H.;Briggs;M.;Viruslike particles in serum of patients with Australia-antigen-associated hepatitis
  6. Am.J.Med.Sci. v.270 Purified and inactivated human hepatitis B vaccine:progress report Hilleman;M.R.;Buynak;E.B.;Roehm;R.R.;Tytell;A.A.;Bertland;A.U.;Lampson;G.P.
  7. Progress in hepatitis B immunization v.194 Significance of Pre-antigens for hepatitis B vaccins Krone;B.;Gerlich;W.H.;Herermann;K.H.;Lenz;A.;Lu;X.;Seiter;M.;Tomslen;R.
  8. J. Infect. Dis. v.122 Hepatitis virus:effect of heat on the infectivity and antigenicity of the MS-1 and MS-2 strains Krugman;S.;Ciles;J.P.;Hammond;J.
  9. N. Engl. J. Med. v.288 Viral hepatitis virus;type B(MS-2strain).Further observations on natural history and preventionHepatitis virus:effect of heat on the infectivity and antigenicity of the MS-1 and MS-2 strains Krugman;S.;Ciles;J.P.
  10. Korean J. Immunol. v.9 Heat aggregated hepatitis B surface antigen and its effect on immune response Lee;S.O.;Soh;J.M.;Park;B.H.;Min;B.K.
  11. Biotechnology v.3 Expression of amplified hepatitis B virus surfac antigen genes in chinese hamster ovary cells Michel;M.L.;Sobczak;E.;Malpiece;Y.;Toillais;P.;Streek;R.E.
  12. Proc. Natl. Acad. USA. v.81 Synthesis in animal all of hepatitis B surface antigen particles carrying a receptor for polymerized human serum albumin Michel;M.L.;Pontisso;P.Sobczak;E.;Malpiece;Y.;Streek;R.E.;Tiollais;P.
  13. Vaccine v.4 Antibodies to a synthetic peptide from the pre-S 102-145 region of the hepatitis B virus envelope are virus neutralizing Neurath;A.R.
  14. Biochem. Biophs. Res. Comn. v.140 Production of antibodies recognizing a heptitis B virus(HBV) surface antigen by administration of murabutide associated to a synthetic pre-S. HBV peptide conjugated to a toxoid career Przewlocki;G.;Audibert;F.;Jolivet;M.;Chdid;L.;Kent;S.B.H.;Neurath;A.R.
  15. Am. J. Med. Sci. v.270 Hepatitis B subunit vaccine:a preliminary report of safety and efficacy tests in chimpanzees Purcell;R.H.;Gerlin;J.L.
  16. Antiviral Res. v.270 Heat-inactivated HBsAg as a vaccine against hepatitis B Reesink;H.W.;Reerink-Brongers;E.E.;Brummelhuis;H.G.;Lafeberschut;L.I.P.
  17. J. Virol. v.63 Dengue virus specific murine T lymphocyte proliferation serotype specificity and responses to recombinant voral proteins Rothman;A.L.;Kurane;I.;Mason;P.W.;Innis;B.L.;Ennis;F.A.
  18. Vaccine v.7 Expression of hepatitis B virus surface antigen containing the Pre-S region in mammalian cell culture system Samanta;H.Youn;B.W.
  19. Science v.213 Biology of hepatitis B virus Tiollais;P.;Charnay;P.;Vyas;G.N.
  20. Nature v.298 Synthesis and assembly of hepatitis B virus surface antigen particles in yeast Valenzuela;P.Medina;A.;Rutter;W.J.Ammerer;G.;Hall;B.D.